The use of biologic-based therapeutics has revolutionized our ability to treat complex diseases such as cancer- and autoimmune-related disorders. Biologic-based therapeutics are known to generate anti ...

Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Latent Lab's AI platform, built on Latent-X2, to access ...

The assessment of immunogenicity in biotherapeutics is crucial to ensuring both the safety and efficacy of these advanced medicinal products. By detecting anti-drug antibodies (ADAs) and understanding ...

UPPSALA, Sweden--(BUSINESS WIRE)--Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the ...

From the 1980s, therapeutic protein drugs — monoclonal antibodies, proteins, antibody-drug conjugates, bispecific antibodies, etc. — have been widely employed in the treatment of HIV, tumors and other ...

In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents that leverage the human immune system to fight cancer, such as checkpoint inhibitors, vaccine-based ...

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer. Cell-Based ...

Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab ® Generic ...